Publications by authors named "L McMahon"
Background: Alzheimer's disease disproportionately affects women in the U.S., with two-thirds of individuals diagnosed being female.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) pathology can start accumulating 20-30 years before cognitive symptoms occur, with increases in inflammation, amyloid-β (Aβ), and hyperphosphorylated Tau during this time. Previous studies have shown that the post-translational modification of a single N-acetylglucosamine moiety to serine or threonine residues to cytosolic or nuclear proteins, known as O-GlcNAcylation, can modify a plethora of cellular processes, including the processing of the amyloid precursor protein, competing with phosphorylation on tau, as well as having anti-inflammatory effects. This study is designed to evaluate how increasing O-GlcNAcylation is impacting AD pathology in the most comprehensive AD rat model to date, the TgF344-AD rat model.
View Article and Find Full Text PDFIntroduction And Objectives: Clozapine is the antipsychotic medication with the greatest efficacy in treatment-resistant schizophrenia (TRS). Unfortunately, clozapine is ceased in approximately 0.2% to 8.
View Article and Find Full Text PDFPatent Review of Novel Biologics Targeting Opioid Use Disorder (2018-2024).
ACS Chem Neurosci
December 2024
Article Synopsis
- In 2023, over 107,000 drug overdose deaths occurred in the U.S., with opioids responsible for approximately 80,000 of these fatalities, primarily due to synthetic opioids like fentanyl.
- New biologics, such as monoclonal antibodies and peptides, are emerging as innovative treatments for opioid overdose and opioid use disorder (OUD) by blocking opioids from affecting the central nervous system and reducing potential for abuse.
- The review highlights recent patents on these biologics and discusses their potential to prevent renarcotization, a risk where overdose patients can relapse into overdosing after being treated with naloxone.